Sarilumab plus methotrexate suppresses circulating biomarkers of bone resorption and synovial damage in patients with rheumatoid arthritis and inadequate response to methotrexate: a biomarker study of MOBILITY

BACKGROUND: Interleukin 6 (IL-6) signaling plays a key role in the pathophysiology of rheumatoid arthritis (RA) and is inhibited by sarilumab, a human monoclonal antibody blocking the IL-6 receptor alpha (IL-6Rα). The effects of sarilumab plus methotrexate (MTX) on serum biomarkers of joint damage a...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Arthritis Res Ther
Auteurs principaux: Boyapati, Anita, Msihid, Jérôme, Fiore, Stefano, van Adelsberg, Janet, Graham, Neil M. H., Hamilton, Jennifer D.
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2016
Sujets:
Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5052933/
https://ncbi.nlm.nih.gov/pubmed/27716324
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13075-016-1132-9
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires